FDA-BLA761530
Document details
Summary
LUMVOA (veligrotug) was approved on June 26, 2026 as a new molecular entity administered intravenously, placing it squarely in the Part B billing pathway as a provider-administered injectable. As a brNew IV injectable LUMVOA enters Part B; J-code pending.
Affected specialty
Ophthalmology alerts →Source document
https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/761530Orig1s000ltr.pdfCLV Intelligence summarizes publicly available federal publications. Not affiliated with or endorsed by any government agency.
Related alerts
4Policy FDA-NDA021980 · Ophthalmology
Fluorescite (Fluorescein Sodium) is approved as an injectable drug, which suggests it will qualify for a J-code assignment for Medicare billing. As an injectable and likely high-cost therapy, it may b
View alertPolicy FDA-BLA761480 · Ophthalmology
The billing pathway for RANLUSPEC cannot be determined until the FDA label publishes. Billing teams should verify against the label for the final route of administration and associated billing details
View alertPolicy LCD-L34760 · Ophthalmology
The new LCD on SCODI by WPS introduces specific guidelines that could impact the billing processes for ophthalmic diagnostic imaging services. Practices may need to adjust their coding and ensure comp
View alertPolicy LCD-L38026 · Ophthalmology
The new LCD on Corneal Hysteresis will likely streamline the billing process for ophthalmology services, ensuring that necessary tests are covered under Medicare. Providers should prepare for potentia
View alert